Treatment of metastatic melanoma: A multidisciplinary approach

Paolo Fava, Chiara Astrua, Martina Sanlorenzo, Simone Ribero, Matteo Brizio, Andrea R. Filippi, Elena Marra, Franco Picciotto, Dario Sangiolo, Fabrizio Carnevale-Schianca, Massimo Aglietta, Sergio Sandrucci, Umberto Ricardi, Virginia Caliendo, Pietro Quaglino, Maria T. Fierro

Research output: Contribution to journalReview articlepeer-review


The prognosis of stage IV metastatic melanoma is poor. An overall 1-year survival of 25.5% and a median survival of 6.2 months were reported without any significant improvement during the last 30 years before the introduction of new drugs (immune checkpoint inhibitors and targeted therapies) which completely modified the therapeutic approach and induced an overwhelming improvement on the survival rates of these patients. This review will analyze the therapeutic tools available for the treatment of patients with metastatic melanoma, including adjuvant interferon and locoregional therapies (surgery, radiotherapy and electrochemotherapy) and will mainly focus on the presentation of results obtained by the new treatments (checkpoint inhibitors and targeted therapies).

Original languageEnglish
Pages (from-to)241-261
Number of pages21
JournalGiornale Italiano di Dermatologia e Venereologia
Issue number3
Publication statusPublished - Jan 1 2017


  • Electrochemotherapy
  • Melanoma
  • Molecular targeted therapy
  • Neoplasm metastasis
  • Radiotherapy

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Treatment of metastatic melanoma: A multidisciplinary approach'. Together they form a unique fingerprint.

Cite this